- Home
- NMRA vs CDLX Comparison
NMRA vs CDLX Comparison
Compare NMRA & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- CDLX
- Stock Information
- Founded
- NMRA 2019
- CDLX 2008
- Country
- NMRA United States
- CDLX United States
- Employees
- NMRA N/A
- CDLX N/A
- Industry
- NMRA
- CDLX Computer Software: Programming Data Processing
- Sector
- NMRA
- CDLX Technology
- Exchange
- NMRA Nasdaq
- CDLX Nasdaq
- Market Cap
- NMRA 121.0M
- CDLX 98.2M
- IPO Year
- NMRA 2023
- CDLX 2018
- Fundamental
- Price
- NMRA $0.84
- CDLX $1.80
- Analyst Decision
- NMRA Buy
- CDLX Hold
- Analyst Count
- NMRA 8
- CDLX 5
- Target Price
- NMRA $9.29
- CDLX $3.50
- AVG Volume (30 Days)
- NMRA 1.4M
- CDLX 1.1M
- Earning Date
- NMRA 08-05-2025
- CDLX 08-06-2025
- Dividend Yield
- NMRA N/A
- CDLX N/A
- EPS Growth
- NMRA N/A
- CDLX N/A
- EPS
- NMRA N/A
- CDLX N/A
- Revenue
- NMRA N/A
- CDLX $272,588,000.00
- Revenue This Year
- NMRA N/A
- CDLX N/A
- Revenue Next Year
- NMRA N/A
- CDLX $5.51
- P/E Ratio
- NMRA N/A
- CDLX N/A
- Revenue Growth
- NMRA N/A
- CDLX N/A
- 52 Week Low
- NMRA $0.61
- CDLX $1.22
- 52 Week High
- NMRA $17.19
- CDLX $9.48
- Technical
- Relative Strength Index (RSI)
- NMRA 52.19
- CDLX 54.71
- Support Level
- NMRA $0.72
- CDLX $1.59
- Resistance Level
- NMRA $0.85
- CDLX $1.83
- Average True Range (ATR)
- NMRA 0.07
- CDLX 0.21
- MACD
- NMRA -0.01
- CDLX 0.01
- Stochastic Oscillator
- NMRA 62.35
- CDLX 52.94
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About CDLX Cardlytics Inc.
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.